Surveillance Protocols

Surveillance Protocols - Watching for Trouble

• Primary Goals: Early detection of:
  • Local recurrence.
  • Distant metastases (esp. lungs, bone).
  • Second primary tumors.
  • Late treatment effects.
• Guiding Principles: Risk-stratified (tumor type, grade, stage), patient-specific, multidisciplinary team essential.
• Common Tools:
  • Clinical assessment (symptoms, function).
  • Imaging: X-ray, MRI (local site), CT chest (metastases), PET-CT (equivocal findings/systemic).
  • Blood markers: LDH, ESR, ALP (monitor trends, not diagnostic alone).
• Typical Follow-up: Intensive first 2-3 years (e.g., q 3-6 months), then reduced frequency (q 6-12 months) up to 5-10 years, then annually or PRN.

⭐ For high-grade sarcomas like Osteosarcoma and Ewing Sarcoma, pulmonary metastases are the most common site of distant failure; meticulous chest surveillance (CT scans) is critical.

Surveillance Protocols - Peeking Inside

• Goals: Detect recurrence (local/distant), monitor treatment response/complications.
• Key Modalities & Roles:
  • X-ray: Baseline, local bone changes, hardware. Cost-effective.
  • MRI: Superior for local recurrence (soft tissue, marrow); contrast aids activity assessment.
  • CT Scan:
    • Chest: Lung metastases (most common).
    • Abdomen/Pelvis: As indicated by tumor type.
    • Bone windows: Skeletal metastases.
  • PET-CT: Whole-body scan for metabolic activity; detects occult disease, monitors response.
  • Bone Scan (Tc-99m MDP): Screens for osseous metastases; less specific.
• Frequency: Varies by tumor (type, grade, stage).
  • High-grade: More intensive, e.g., every 3-6 months for 2-3 years, then annually up to 5-10 years.

⭐ Chest CT is paramount for osteosarcoma/Ewing's sarcoma surveillance due to high risk of lung metastases.

Surveillance Protocols - Tailored Watch

• Individualized based on tumor type, grade, stage, and treatment. Goal: Early detection of recurrence & management of long-term sequelae.

Surveillance Protocols - Beyond the Battle

• Goal: Detect recurrence, manage treatment sequelae (e.g., ↓ROM, lymphedema, secondary malignancy), & monitor implant integrity.
• Schedule: Varies by tumor type/grade; typically frequent initially (e.g., 3-6 monthly for 2-5 yrs), then annually.
• Modalities: Clinical exam, imaging (X-ray, MRI, CT, PET-CT), blood markers.
• Address psychosocial well-being & functional rehabilitation.

⭐ Regular follow-up is crucial as late recurrences (beyond 5 years) can occur, especially in high-grade sarcomas; also monitor for radiation-induced sarcomas or chemotherapy-related cardiotoxicity/nephrotoxicity long-term (💡).

High‑Yield Points - ⚡ Biggest Takeaways

• Regular follow-up is crucial for early detection of local recurrence or distant metastasis.
• Imaging protocols (X-ray, MRI, CT, PET-CT) vary by tumor type, grade, and stage.
• Osteosarcoma and Ewing sarcoma require long-term surveillance (often ≥10 years) for late recurrences.
• Surveillance for benign aggressive tumors (e.g., GCT) primarily targets local recurrence.
• Chest imaging (CT preferred) is standard for detecting pulmonary metastases.
• Biomarkers (LDH, ALP) may supplement imaging in specific sarcomas_